Psoriatic Arthritis News

Healio spoke with Philip J. Mease, MD, about ongoing research in psoriatic arthritis.

Healio spoke with Philip J. Mease, MD, about factors to consider when making psoriatic arthritis treatment decisions.

Healio spoke with Philip J. Mease, MD, about non-pharmacological and complementary management options in psoriatic arthritis.

Healio spoke with Philip J. Mease, MD, about recent advancements in psoriatic arthritis.

Johnson & Johnson has settled its lawsuit with Amgen regarding the latter company’s Stelara biosimilar, clearing the way for a January 2025 release date in the United States, according to results of a federal court filing.

Patients with psoriatic arthritis and axial involvement experienced greater improvement when treated with upadacitinib 15 mg compared with placebo and adalimumab, according to data published in Arthritis Research & Therapy.

Patients with immune checkpoint inhibitor-associated inflammatory arthritis who receive a biologic DMARD demonstrate quicker arthritis control, but also experience faster cancer progression, vs. methotrexate, according to data.

At the 2023 European Congress of Rheumatology, Amgen presented study results evaluating the use of Otezla for the treatment of psoriatic arthritis, according to a company press release.

Patients with anxiety or depression are less likely to exhibit healthy self-management for their rheumatoid arthritis, psoriatic arthritis or axial spondyloarthritis, according to data presented at EULAR 2023 Congress.

EULAR has removed the use of systemic glucocorticoids from its recommendations for the management of psoriatic arthritis, according to a presentation at the EULAR 2023 Congress.